Farxiga Trials Show Reduced Risk of Death and Worsening Heart Failure

By PacConAdmin | August 29, 2022

AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) cut the risk of cardiovascular death and worsening heart failure by 16.4 percent relative to placebo, researchers announced at the European Society of Cardiology Congress in Barcelona.
Source: Drug Industry Daily

Posted in Drug Industry Daily